We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+6.99%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$184M
AUM Growth
+$42.5M
Cap. Flow
+$36.1M
Cap. Flow %
19.61%
Top 10 Hldgs %
31.33%
Holding
99
New
45
Increased
12
Reduced
8
Closed
29

Top Buys

1
ZBH icon
Zimmer Biomet
ZBH
+$5.07M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.94M
3
CYBX
CYBERONICS INC
CYBX
+$4.32M
4
AGN
Allergan Inc
AGN
+$4.15M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$4.09M

Top Sells

1
MDVN
MEDIVATION, INC.
MDVN
+$6.17M
2
COO icon
Cooper Companies
COO
+$5.42M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.24M
4
BSX icon
Boston Scientific
BSX
+$5.11M
5
INSM icon
Insmed
INSM
+$4M

Sector Composition

1 Healthcare 63.11%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
51
DELISTED
bluebird bio
BLUE
$1.26M 0.68%
+2,702
New +$1.25M
AGIO icon
52
Agios Pharmaceuticals
AGIO
$2.36B
$1.23M 0.67%
+20,000
New +$862K
PBYI icon
53
Puma Biotechnology
PBYI
$434M
$1.19M 0.65%
5,000
+4,000
+400% +$821K
ALIM
54
PUT
DELISTED
Alimera Sciences
ALIM
$1.08M 0.59%
+13,333
New +$1.14M
VNDA icon
55
CALL
Vanda Pharmaceuticals
VNDA
$327M
$1.04M 0.56%
+100,000
New +$1.31M
NSTG
56
DELISTED
NanoString Technologies, Inc.
NSTG
$985K 0.53%
90,000
+20,000
+29% +$247K
ARCT icon
57
CALL
Arcturus Therapeutics
ARCT
$172M
$772K 0.42%
+7,143
New +$931K
RCPT
58
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$764K 0.41%
12,300
-22,700
-65% -$1.08M
BIOL
59
DELISTED
Biolase, Inc.
BIOL
$747K 0.41%
24
– –
OCRX
60
DELISTED
Ocera Therapeutics, Inc.
OCRX
$613K 0.33%
125,000
+25,000
+25% +$144K
HRTX icon
61
Heron Therapeutics
HRTX
$89.1M
$583K 0.32%
70,000
– –
LPCN icon
62
Lipocine
LPCN
$18.4M
$561K 0.3%
+5,398
New +$671K
ASMB icon
63
Assembly Biosciences
ASMB
$531M
$532K 0.29%
5,417
+2,084
+63% +$185K
EYPT icon
64
EyePoint Inc
EYPT
$1.12B
$442K 0.24%
+10,000
New +$451K
UNIS
65
DELISTED
Unilife Corporation
UNIS
$344K 0.19%
15,000
-15,000
-50% -$379K
CPRX icon
66
PUT
Catalyst Pharmaceutical
CPRX
$332K 0.18%
+100,000
New +$261K
FLXN
67
DELISTED
Flexion Therapeutics, Inc.
FLXN
$228K 0.12%
+12,488
New +$181K
AMRN
68
Amarin Corp
AMRN
$292M
$218K 0.12%
+10,000
New +$326K
ARAY icon
69
Accuray
ARAY
$30.8M
– –
-250,000
Closed -$2.2M
ASRT
70
PUT
DELISTED
Assertio
ASRT
– –
-2,000
Closed -$1.67M
AVDL
71
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-75,000
Closed -$1.13M
BSX icon
72
Boston Scientific
BSX
$65.4B
– –
-400,000
Closed -$5.11M
COO icon
73
Cooper Companies
COO
$14B
– –
-160,000
Closed -$5.42M
CPRX icon
74
Catalyst Pharmaceutical
CPRX
– –
-437,296
Closed -$1.14M
FOLD
75
DELISTED
Amicus Therapeutics
FOLD
– –
-600,000
Closed -$2M
1 2
3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2014 Portfolio in Review

As of Q3 2014, Ghost Tree Capital held 99 positions worth $184M, up 30% from $142M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Ghost Tree Capital deployed $36.1M of net new capital in Q3 2014, opening 45 new positions and adding to 12 existing holdings. Its largest new stake was Zimmer Biomet: 51,500 shares worth $5.03M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 60% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Allergan plc, an estimated $3.36M trimmed.

  • Ghost Tree Capital's largest Q3 2014 buy was Zimmer Biomet: 51,500 shares worth $5.03M.
  • Ghost Tree Capital added most to TherapeuticsMD in Q3 2014, an estimated $2.52M increase.
  • Ghost Tree Capital's biggest Q3 2014 reduction was Allergan plc, cutting an estimated $3.36M.
  • Ghost Tree Capital fully exited MEDIVATION, INC. in Q3 2014, selling an estimated $6.17M.
  • Ghost Tree Capital's ten largest holdings make up 31% of its $184M portfolio in Q3 2014.
  • Ghost Tree Capital opened 45 new positions and closed 29 in Q3 2014.
  • Ghost Tree Capital's portfolio value rose 30% quarter-over-quarter to $184M.

Based on Ghost Tree Capital's 13F filing for Q3 2014, filed 14 Nov 2014.